Replies to post #58495 on Biotech Values

[DewDiligence]

Re: HCV most likely to succeed

>You don't think much of ACHN and GILD new replicase inhibitor…<

I wasn’t passing judgment on it one way or the other. Paragraph 6 and paragraph 8 in #msg-26284312 are intended to be catchall entries for various drugs with established and novel MoA’s, respectively. (Hence the use of “e.g.” in the narratives :-) ) Regards, Dew

[DewDiligence]

Re: ACHN’s HCV pipeline

>You don't think much of ACHN and GILD new replicase inhibitor because the lead one was halted after nephrotoxicity? I think the new one will enter into the clinic in mid 08.<

According to today’s ACHN CC, ACH-1095 (a.k.a. GS9525) will enter the clinic in 4Q08.

>ACHN also has an HCV protease inhibitor in preclinical that has produced low-single-digit nano-molar activity in the replicon assay.<

It’s called ACH-1625 (#msg-29791560); according to today’s CC, ACH-1625 will enter the clinic in 1Q09.

There’s new info on this compound on ACHN’s webste (with more to come in the way of hard data on 9/5/08):

http://www.achillion.com/PL/pdf/Sum08_1625.pdf
http://www.achillion.com/main.aspx?pn=1625


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”